Overview of the Pharmaceutical Industry and New Drug Market Trends: Part I – Perspectives and Insights provides a comprehensive analysis of the global pharmaceutical industry , highlighting corporate rankings, market evolution, and long-term trends from 2013 to 2024. This volume examines the performance of the top 30 pharmaceutical companies , tracking their sales, market shifts, and R&D strategies over 12 years. Key developments include: Pfizer regained the top position with COVID-19 vaccines after a temporary decline following the Viatris spin-off. - Merck rose to 2nd place on the strength of Keytruda , approaching $30 billion in sales. - Johnson & Johnson , driven by Stelara and Darzalex , climbed from 7th to 3rd place. - AbbVie advanced after the Allergan merger , but patent expirations of Humira impacted its ranking. - GLP-1 agonists propelled Eli Lilly and Novo Nordisk , reshaping mid-tier company rankings. - Companies such as AstraZeneca, Sanofi, Novartis, Roche, and Takeda faced patent expirations, portfolio spin-offs, and competition from biosimilars, highlighting the industry’s dynamic landscape. By 2024, the top six companies exceeded $50 billion in annual sales, with Pfizer surpassing $60 billion, while the next tier reached $40 billion, leaving only Takeda and Amgen in the $30 billion range. Industry Transformation Over Four Decades: This book also traces long-term industry themes since 1985, summarizing target diseases, technological innovations, and management challenges in 10-year intervals, providing historical context to today’s market dynamics. Ideal for investors, industry analysts, researchers, and pharmaceutical professionals , this volume offers authoritative insights into market trends, corporate strategies, and the evolution of global pharmaceutical innovation . DATABOOK 2024 – Part III provides an in-depth analysis of the global pharmaceutical industry with a focus on pharmacology classes. This volume explores the latest trends in prescription drugs, new drug development, and market dynamics across therapeutic areas. Readers will gain comprehensive insights into: Market rankings of top prescription drugs worldwide - Pharmacology class–specific sales and growth trends - Pipeline developments and regulatory milestones - Emerging opportunities in biologics, small molecules, and novel modalities Part IV – Pharmaceutical Companies . This volume provides a comprehensive analysis of 2024 new drug development from the top 30 global pharma companies , covering approvals, clinical studies, regulatory milestones, and business development activities. Key insights include: - Global New Drug Market: ~300 prescription products totaling $691 billion in 2024, up 8% YoY. - Company Groups: Top 10: Pfizer, Merck, J&J, AbbVie, AstraZeneca, Roche, Novartis, BMS, Eli Lilly, Sanofi - Mid-Tier: Novo Nordisk, GSK, Amgen, Takeda, Gilead, Bayer, Regeneron, Astellas, Daiichi Sankyo, Otsuka - Biotech & Others: Vertex, Biogen, Chugai, UCB, Eisai, Incyte, Lundbeck, Alnylam, Boehringer Ingelheim - R&D Highlights: 28 initial approvals, 61 additional approvals, 135 clinical advances, and 9 licensing deals. - Pipeline: 362 drugs across 572 Phase 3+ projects, with oncology and immunology as dominant focus areas.